Asarum Canadense Root

Dosage for Asarum Canadense Root allergenic extract is highly individualized and must be determined by an allergist based on the patient's clinical history and reactivity. There is no 'standard' dose applicable to all patients.

Diagnostic Dosing

• Prick/Puncture Test: Usually, one drop of a 1:10 or 1:20 w/v concentration is applied to the skin. A sterile lancet is used to prick the skin through the drop.
• Intradermal Test: If the prick test is negative, a much more dilute solution (0.02 mL to 0.05 mL of a 1:1000 w/v or 1:100 w/v solution) may be injected into the dermis.

Immunotherapy Dosing

• Build-up Phase: Treatment typically begins with a very low dose (e.g., 0.05 mL of a 1:10,000 w/v dilution) administered subcutaneously once or twice weekly. The dose is gradually increased according to the patient's tolerance.
• Maintenance Phase: Once the target 'maintenance dose' is reached (often 0.5 mL of a 1:100 or 1:20 w/v concentration), the interval between injections is increased to every 2 to 4 weeks.

Asarum Canadense Root extracts are used in children, but extreme caution is required. Pediatric dosing follows the same principles as adult dosing, starting with highly dilute solutions and titrating upward based on the child's specific sensitivity. Children may be at a higher risk for systemic reactions if they have poorly controlled asthma. Clinical studies have not established a specific minimum age, but immunotherapy is rarely started in children under the age of 5 due to the difficulty of monitoring for early signs of systemic reactions.

Renal Impairment

No specific dosage adjustments are provided for renal impairment; however, patients with compromised kidney function should be monitored closely, as their ability to clear inflammatory mediators released during a reaction may be theoretically altered.

Hepatic Impairment

No dosage adjustments are required for hepatic impairment, as the metabolism of allergenic proteins is primarily proteolytic and not dependent on hepatic CYP450 enzymes.

Elderly Patients

Elderly patients often have a higher prevalence of cardiovascular disease. Because the treatment of a systemic reaction (anaphylaxis) involves the use of epinephrine, which can stress the heart, the benefit-risk ratio must be carefully evaluated in patients over 65.

Asarum Canadense Root extract is never self-administered by the patient at home. It must be administered in a clinical setting.

• Administration Site: Immunotherapy injections are given subcutaneously in the posterior aspect of the upper arm.
• Observation Period: Patients must remain in the physician's office for at least 30 minutes after any injection. Most fatal systemic reactions occur within this window.
• Storage: Extracts must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). They should never be frozen.
• Activity: Patients should avoid vigorous exercise for at least 2 hours before and after the injection, as increased blood flow can accelerate allergen absorption and increase the risk of a systemic reaction.

In the context of immunotherapy, a missed dose can lead to a loss of tolerance. If a dose is missed by more than a few days, the allergist may need to reduce the next dose to ensure safety. If several weeks are missed, the build-up process may need to be restarted from a lower concentration.

An 'overdose' in the context of allergenic extracts usually refers to the administration of a dose that exceeds the patient's current threshold of tolerance.

• Signs: Rapid onset of hives, swelling of the throat, wheezing, hypotension (low blood pressure), and loss of consciousness.
• Emergency Measures: Immediate administration of intramuscular epinephrine (0.3 mg for adults, 0.15 mg for children), oxygen, intravenous fluids, and antihistamines. Emergency medical services (911) must be contacted immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Local reactions are the most frequent side effects associated with Asarum Canadense Root allergenic extracts, occurring in nearly all patients during skin testing or the build-up phase of immunotherapy.

• Local Erythema (Redness): A red area around the injection or prick site is expected. It typically appears within minutes and may last for several hours.
• Local Pruritus (Itching): Intense itching at the site of administration is a direct result of histamine release in the skin.
• Wheal Formation: A raised, white or pale bump (similar to a mosquito bite) at the test site. In immunotherapy, a local swelling larger than the size of a quarter may indicate the need to adjust the dose downward.

These reactions are often referred to as 'large local reactions' or mild systemic symptoms.

• Delayed Local Swelling: Swelling that appears 6 to 24 hours after an injection. While not immediately dangerous, it must be reported to the doctor before the next dose.
• Fatigue: Some patients report feeling unusually tired for a few hours following an immunotherapy session.
• Mild Rhinitis: Sneezing or a runny nose shortly after the administration of the extract.

Rarely, patients may experience more significant systemic issues that do not immediately progress to full anaphylaxis.

• Generalized Urticaria (Hives): Hives appearing on parts of the body far from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Mild Bronchospasm: A slight tightening of the chest or a dry cough.

> Warning: Stop taking Asarum Canadense Root and call your doctor immediately if you experience any of these.

• Anaphylaxis: This is a life-threatening allergic reaction. Symptoms include a sudden drop in blood pressure, a rapid or weak pulse, narrowing of the airways, and a swollen tongue or throat.
• Syncope (Fainting): May occur due to a vasovagal response or as a sign of impending circulatory collapse.
• Severe Dyspnea (Shortness of Breath): Indicates significant airway obstruction or pulmonary involvement.
• Cyanosis: A bluish discoloration of the skin or lips, indicating a lack of oxygen in the blood.

When used as an allergenic extract, long-term side effects are rare because the substance is not a systemic drug. However, the primary concern with the Asarum genus is the potential for Aristolochic Acid Nephropathy (AAN). While the tiny amounts used in allergy shots are not known to cause this, historical use of wild ginger as an oral supplement has been linked to irreversible kidney damage and upper urinary tract cancers. Therefore, Asarum Canadense Root should never be ingested as a tea or supplement.

Allergenic extracts, including Asarum Canadense Root, carry a class-wide warning regarding the risk of severe systemic reactions.

• Warning: This product can cause severe, life-threatening systemic reactions, including anaphylaxis. It should only be administered by healthcare providers trained in the management of anaphylaxis and in facilities equipped with emergency resuscitation equipment, including epinephrine. Patients with unstable or severe asthma are at increased risk for fatal reactions.

Report any unusual symptoms to your healthcare provider.

Asarum Canadense Root extract is a potent biological agent. It is intended only for use by physicians experienced in the diagnosis and treatment of allergic diseases. Because of the risk of severe systemic reactions, patients must be screened for underlying conditions that might complicate the treatment of anaphylaxis, such as heart disease or the use of certain medications like beta-blockers.

No FDA black box warnings for Asarum Canadense Root specifically exist as a unique entity, but it falls under the general black box warning for all Non-Standardized Allergenic Extracts. The warning emphasizes that these products can cause anaphylaxis and must be administered in a setting where emergency medical care is immediately available. Patients must be observed for at least 30 minutes post-injection.

• Anaphylaxis Risk: The primary risk is a systemic allergic reaction. This risk is higher during the build-up phase of immunotherapy, when a new vial is started, or if the patient is highly sensitive.
• Asthma Stability: Patients with asthma must have their condition well-controlled (e.g., FEV1 > 70% of predicted) before receiving an injection. An asthma flare-up significantly increases the risk of a fatal reaction to the extract.
• Aristolochic Acid Content: Although the extract is for immunological use, the raw plant contains aristolochic acid. Patients should be warned never to ingest the root or use it as a herbal remedy due to the risk of nephrotoxicity (kidney poisoning).
• Infection/Illness: Injections should be postponed if the patient has an acute infection, fever, or respiratory illness, as these can lower the threshold for a systemic reaction.

• Post-Injection Observation: Mandatory 30-minute wait time in the clinic.
• Lung Function: For asthmatic patients, peak flow or spirometry may be checked before administration.
• Skin Assessment: The injection site must be checked for large local reactions before the patient leaves and again before the next scheduled dose.

While the extract itself does not cause sedation, a systemic reaction or the administration of epinephrine to treat a reaction can significantly impair the ability to drive or operate machinery. Patients should ensure they feel completely normal before leaving the clinic.

Alcohol consumption should be avoided on the day of an injection. Alcohol causes vasodilation (widening of blood vessels), which may increase the rate of allergen absorption and potentially worsen a systemic reaction.

If a patient experiences a severe systemic reaction, the physician will carefully re-evaluate the need for immunotherapy. In many cases, the treatment is discontinued, or the dose is significantly reduced. Unlike some medications, there is no 'withdrawal' syndrome associated with stopping allergenic extracts, but the patient's allergy symptoms will likely return to their baseline level over time.

> Important: Discuss all your medical conditions with your healthcare provider before starting Asarum Canadense Root.

• Beta-Blockers (e.g., Propranolol, Atenolol): These are contraindicated in many immunotherapy protocols. Beta-blockers can make a systemic reaction more severe and, more importantly, they block the effects of epinephrine (adrenaline), which is the primary treatment for anaphylaxis. This can make a reaction 'epinephrine-resistant' and potentially fatal.

• ACE Inhibitors (e.g., Lisinopril): These medications may increase the risk of systemic reactions or interfere with the body's compensatory mechanisms during anaphylaxis. Close monitoring or alternative antihypertensive therapy may be required.
• MAO Inhibitors (e.g., Phenelzine): These can interfere with the metabolism of epinephrine, potentially leading to a hypertensive crisis if epinephrine is administered to treat an allergic reaction.

• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these may potentiate the effects of epinephrine, requiring careful management during an emergency.
• Antihistamines (e.g., Cetirizine, Loratadine): These medications can suppress the 'wheal and flare' response during diagnostic skin testing, leading to false-negative results. Patients are usually required to stop antihistamines for 3 to 7 days before testing.

• Alcohol: As mentioned, alcohol can increase the risk of a systemic reaction by increasing blood flow and allergen absorption.
• High-Fat Meals: While not directly interacting with the extract, very heavy meals before an injection may complicate the management of gastrointestinal symptoms of anaphylaxis (nausea/vomiting).

• St. John's Wort: May have minor interactions with the immune response or blood pressure regulation.
• Herbal Stimulants: Supplements containing ephedra or high caffeine levels can complicate the cardiovascular assessment during a reaction.

• Skin Prick Tests: Asarum Canadense Root extract itself is used to perform a lab test. Its results are invalidated by recent use of antihistamines, H2 blockers (like famotidine), or certain antidepressants.
• Total IgE: Immunotherapy may cause a transient rise in total IgE levels before they eventually decline.

For each major interaction, the primary concern is not the direct chemical interaction of the substances, but rather how the secondary drug affects the body's ability to signal an allergic reaction or respond to emergency treatment (epinephrine). The management strategy is always to perform a thorough medication reconciliation before the first dose.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe, Uncontrolled Asthma: Patients whose asthma is not stable are at the highest risk for fatal bronchospasm following an allergen injection. The risk of the procedure outweighs any potential benefit.
• Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The stress of a potential systemic reaction and the subsequent need for epinephrine could cause further cardiac damage.
• Hypersensitivity to Extract Components: If a patient has a known severe allergy to glycerin or phenol (used as preservatives in the extract), the product must not be used.
• Inability to Communicate: Patients who cannot report early symptoms of a reaction (e.g., very young children or those with severe cognitive impairment) may not be suitable candidates for immunotherapy.

• Beta-Blocker Therapy: While often considered an absolute contraindication, some specialists may perform a risk-benefit analysis if no other blood pressure medication is effective. However, this is generally avoided.
• Pregnancy: Immunotherapy is typically not initiated during pregnancy due to the risk of anaphylaxis-induced fetal hypoxia (lack of oxygen). However, if a patient is already on a stable maintenance dose, it may sometimes be continued.
• Autoimmune Diseases: There is a theoretical risk that stimulating the immune system with extracts could exacerbate certain autoimmune conditions, though data on this is limited.

Asarum Canadense is in the Aristolochiaceae family. Patients who have had severe reactions to other members of this family or to plants with similar protein structures may be at increased risk. Furthermore, cross-reactivity with certain pollens or foods (Pollen-Food Allergy Syndrome) should be considered by the allergist during the diagnostic phase.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Asarum Canadense Root.

Asarum Canadense Root extract is classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm. The primary concern during pregnancy is the risk of a systemic reaction in the mother. Anaphylaxis can lead to maternal hypotension and uterine hypoperfusion, resulting in fetal distress or death. Consequently, starting a new course of immunotherapy during pregnancy is generally avoided. If a patient becomes pregnant while on a maintenance dose, the physician may choose to continue the current dose but will not increase it until after delivery.

It is not known whether the allergenic proteins from Asarum Canadense Root are excreted in human milk. However, because these are large proteins that are likely degraded in the mother's system, the risk to the nursing infant is considered low. The primary consideration is the mother's safety and the potential need for emergency medications. Most experts consider immunotherapy compatible with breastfeeding.

Allergenic extracts are used in the pediatric population for both diagnosis and treatment. However, the safety and efficacy of Asarum Canadense Root specifically have not been established in large-scale pediatric clinical trials. The main challenge in children is their limited ability to describe the 'aura' or early symptoms of a systemic reaction (such as an itchy throat or a sense of 'impending doom'). Extra caution and extended observation times may be warranted for younger children.

Clinical studies of Asarum Canadense Root extract did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. In general, the use of this extract in elderly patients requires a careful assessment of cardiovascular health. The elderly are more likely to have underlying coronary artery disease, making them more vulnerable to the effects of both anaphylaxis and the epinephrine used to treat it.

There are no specific guidelines for the use of Asarum Canadense Root in patients with renal impairment. However, given the potential for aristolochic acid (found in the source plant) to be nephrotoxic, patients with pre-existing kidney disease should be monitored closely, even though the amount of the toxin in a processed allergenic extract is negligible.

Since the clearance of allergenic proteins does not rely on the liver's metabolic pathways, hepatic impairment is not expected to significantly affect the safety or efficacy of the extract. No dose adjustments are typically required for patients with liver disease.

> Important: Special populations require individualized medical assessment.

Asarum Canadense Root allergenic extract acts as an immunomodulator. The primary active components are the various proteins and glycoproteins found in the root. When introduced to a sensitized individual, these allergens cross-link IgE antibodies on the surface of mast cells. This triggers a signaling cascade involving tyrosine kinases (such as Syk), leading to the release of pre-formed mediators (histamine) and the synthesis of new mediators (leukotrienes). In the context of immunotherapy, the repeated exposure leads to the desensitization of these cells and a shift in the T-cell population toward a regulatory phenotype.

• Onset of Action: For skin testing, the onset of the 'wheal and flare' reaction is rapid, typically peaking within 15 to 20 minutes. For immunotherapy, the onset of clinical benefit is slow, often taking 6 to 12 months of regular injections to see a reduction in allergy symptoms.
• Duration of Effect: The diagnostic skin reaction subsides within a few hours. The therapeutic effect of immunotherapy can be long-lasting, sometimes persisting for years after the 3-to-5-year treatment course is completed.
• Tolerance: The goal of treatment is to induce 'clinical tolerance,' where the patient no longer reacts to environmental exposure to the allergen.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local/Subcutaneous) |

| Protein Binding | Minimal systemic binding |

| Half-life | Varies by protein (hours) |

| Tmax | 15-30 minutes (local) |

| Metabolism | Proteolytic degradation |

| Excretion | Renal (metabolites) |

• Molecular Formula: Complex mixture (No single formula) |
• Molecular Weight: Range of 10,000 to 70,000 Daltons (typical for allergens) |
• Solubility: Soluble in aqueous buffers and saline |
• Structure: The extract contains various proteins, including those with enzymatic activity and structural proteins from the plant root.

Asarum Canadense Root is classified as a Non-Standardized Plant Allergenic Extract. It is part of a broader group of biologicals used in the field of Allergy and Immunology. Related medications include other non-standardized extracts such as Goldenrod, Dandelion, and various tree or grass pollens not yet standardized by the FDA.